Investigational Drug Information for LY3871801
✉ Email this page to a colleague
What is the development status for investigational drug LY3871801?
LY3871801 is an investigational drug.
There have been 5 clinical trials for LY3871801.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 11th 2023.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and [disabled in preview]. The leading clinical trial sponsors are Eli Lilly and Company, Rigel Pharmaceuticals, and [disabled in preview].
There are nine US patents protecting this investigational drug and twenty-three international patents.
Summary for LY3871801
| US Patents | 9 |
| International Patents | 23 |
| US Patent Applications | 25 |
| WIPO Patent Applications | 3 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 1 (2023-05-11) |
| Vendors | 7 |
Recent Clinical Trials for LY3871801
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants | Eli Lilly and Company | Phase 1 |
| A Study of LY3871801 in Healthy Asian and Non-Asian Participants | Eli Lilly and Company | Phase 1 |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Rigel Pharmaceuticals | Phase 2 |
Clinical Trial Summary for LY3871801
Top disease conditions for LY3871801
Top clinical trial sponsors for LY3871801
US Patents for LY3871801
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY3871801 | ⤷ Start Trial | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals, Inc. (South San Francisco, CA) | ⤷ Start Trial |
| LY3871801 | ⤷ Start Trial | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals Inc | ⤷ Start Trial |
| LY3871801 | ⤷ Start Trial | RIP1 inhibitory compounds and methods for making and using the same | Rigel Pharmaceuticals Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LY3871801
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LY3871801 | Australia | AU2019262144 | 2038-05-03 | ⤷ Start Trial |
| LY3871801 | Brazil | BR112020022420 | 2038-05-03 | ⤷ Start Trial |
| LY3871801 | Canada | CA3099037 | 2038-05-03 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
